Peanut Allergy Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
PEANUT ALLERGY THERAPEUTICS PIPELINE ANALYSIS
• Peanut allergy is one of the most common types of food allergies caused by a legume, known as peanut, which is common in children as well as adults.
• Peanut is an herbaceous plant that belongs to the family of legumes. It occurs when the body’s immune system depicts an abnormal response for one or more peanut proteins. Individuals are suffering from this allergy exhibit symptoms such as itchy skin, an itching sensation around the mouth or throat, nausea, runny or congested nose, or anaphylaxis.
• The patients suffering from asthma and eczema are also been observed more likely to get the allergy from peanuts. Drop in blood pressure, swelling in the throat, fainting, and blockage of the airway can also occur in severe conditions.
• Even though the specific etiology of peanut allergy is not clear, it can because of the interaction of genetic susceptibility with environmental factors.
• The only available strategy currently for managing peanut allergy is the avoidance and the acute reactions treatment with parenteral epinephrine.
• An experimental peanut oral immunotherapy is prescribed to patients as an investigational treatment. These grassroots efforts can be effective in desensitizing patients to peanut, lack of regulatory agency approval and standardization, making it difficult to ensure the safety of the treatment.
• Many companies are developing drug candidates by using advanced technologies, and the drug candidates have known to show positive efficacy in the clinical and preclinical developmental stages.
• At present, there is no approved drug for the treatment of peanut allergy, leading to a large unmet need in its therapeutic pipeline. The first drug launcher has great benefits. This incredible growth stems from the expected entry of four new peanut immunotherapy products to fulfill the marketplace.
• These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics’ AR-101, Camallergy’s CA-002, Prota Therapeutics’ PPOIT, and one epicutaneous immunotherapy product-DBV Technologies’ Viaskin Peanut.
• The clinical studies analyzed that peanut allergy therapeutics pipeline is comprised of approximately 19 drug candidates present in different stages of development.
• Some of pipeline drug candidates under clinical trial phases of development include Omalizumab, Dupilumab, Viaskin etc, that contribute to the growth of the market. For instance, BioLingus Inc. is utilizing a technology called BioLingus technology, which is a micro-encapsulation process that delivers macromolecules such as peptides and proteins and is particularly effective for sublingual immunotherapy for the treatment of peanut allergy.
• Most of the drug development molecules in the pipeline are under the pre-clinical drug development stage.
• Various technological advancements characterized peanut allergy therapeutics pipeline growth. The increase in the number of patents approvals and improvements in technologies are the major factors driving the growth of the pipeline.
• Some of the other factors strengthening the pipeline growth include; positive clinical as well as preclinical results of various drug candidates and support from various health organizations such as educational institutes and National Institutes of health.
• Peanut allergy is one of the most common types of food allergies caused by a legume, known as peanut, which is common in children as well as adults.
• Peanut is an herbaceous plant that belongs to the family of legumes. It occurs when the body’s immune system depicts an abnormal response for one or more peanut proteins. Individuals are suffering from this allergy exhibit symptoms such as itchy skin, an itching sensation around the mouth or throat, nausea, runny or congested nose, or anaphylaxis.
• The patients suffering from asthma and eczema are also been observed more likely to get the allergy from peanuts. Drop in blood pressure, swelling in the throat, fainting, and blockage of the airway can also occur in severe conditions.
• Even though the specific etiology of peanut allergy is not clear, it can because of the interaction of genetic susceptibility with environmental factors.
• The only available strategy currently for managing peanut allergy is the avoidance and the acute reactions treatment with parenteral epinephrine.
• An experimental peanut oral immunotherapy is prescribed to patients as an investigational treatment. These grassroots efforts can be effective in desensitizing patients to peanut, lack of regulatory agency approval and standardization, making it difficult to ensure the safety of the treatment.
• Many companies are developing drug candidates by using advanced technologies, and the drug candidates have known to show positive efficacy in the clinical and preclinical developmental stages.
• At present, there is no approved drug for the treatment of peanut allergy, leading to a large unmet need in its therapeutic pipeline. The first drug launcher has great benefits. This incredible growth stems from the expected entry of four new peanut immunotherapy products to fulfill the marketplace.
• These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics’ AR-101, Camallergy’s CA-002, Prota Therapeutics’ PPOIT, and one epicutaneous immunotherapy product-DBV Technologies’ Viaskin Peanut.
• The clinical studies analyzed that peanut allergy therapeutics pipeline is comprised of approximately 19 drug candidates present in different stages of development.
• Some of pipeline drug candidates under clinical trial phases of development include Omalizumab, Dupilumab, Viaskin etc, that contribute to the growth of the market. For instance, BioLingus Inc. is utilizing a technology called BioLingus technology, which is a micro-encapsulation process that delivers macromolecules such as peptides and proteins and is particularly effective for sublingual immunotherapy for the treatment of peanut allergy.
• Most of the drug development molecules in the pipeline are under the pre-clinical drug development stage.
• Various technological advancements characterized peanut allergy therapeutics pipeline growth. The increase in the number of patents approvals and improvements in technologies are the major factors driving the growth of the pipeline.
• Some of the other factors strengthening the pipeline growth include; positive clinical as well as preclinical results of various drug candidates and support from various health organizations such as educational institutes and National Institutes of health.
